BioCryst Pharmaceuticals stock gains 2.32 percent at EUR 7.06

Published on 10/20/2026 at 20:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 218.25 million. BioCryst Pharmaceuticals stock costs EUR 7.06 on October 20, 2026, up 2.32 percent versus Tradegate close.

Price and reporting facts

BioCryst stock gained 2.32 percent on October 20, 2026.
Second-quarter revenue reached USD 218.25 million, up 33.60 percent year over year.
BioCryst stock costs EUR 7.06 at Lang & Schwarz on October 20, 2026 at 8:11 p.m. CEST, 2.32 percent above the Tradegate close of October 19, 2026.
BioCryst is scheduled to report third-quarter results on November 2, 2026.

BCRX, US09058V1035, Illustration mit AI erstellt.

BioCryst Pharmaceuticals (ISIN US09058V1035) was trading at EUR 7.06 at Lang & Schwarz on October 20, 2026 at 8:11 p.m. CEST, up EUR 0.16, or 2.32 percent, versus the Tradegate close of October 19, 2026 at EUR 6.90. The move puts the stock price at the center of the daily report, while the company's latest operating figures provide the main business context.

Markets Insider reported on October 9, 2026 that BioCryst generated USD 218.25 million in revenue in the second quarter ended June 30, 2026. Revenue was up 33.60 percent from USD 163.35 million a year earlier, while net profit reached USD 78.40 million versus USD 5.09 million.

What does revenue growth mean?

The second-quarter figures show a larger revenue base than the prior-year period, but the comparison also includes a sharp increase in net profit. The USD 73.31 million revenue gain was accompanied by a USD 73.31 million increase in net profit, based on the figures reported by Markets Insider. The period was also covered by MarketBeat in its October 10, 2026 review of analyst views.

Stock remains below its high

BioCryst's Nasdaq quote was USD 7.92 on October 20, 2026 at 2:15 p.m. ET. The company's 52-week range was USD 6.23 to USD 11.22 as of October 19, 2026, leaving the euro quote 37.08 percent below the upper end and 13.32 percent above the lower end. The reported market capitalization was USD 2.06 billion, while the Nasdaq session had recorded 9.77 million shares of volume.

November 2 is the next date

MarketBeat lists November 2, 2026 as BioCryst's estimated third-quarter reporting date, with the conference call scheduled for 8:30 a.m. ET. Its consensus view calls for USD 165.67 million in revenue and USD 0.0919 in earnings per share, compared with USD 159.40 million and USD 0.06 in the year-earlier quarter.

Price and business context

The current euro quotation sits above the latest Tradegate close, while the stock remains below its 52-week high. For investors, the next scheduled report will provide the next dated comparison for revenue, earnings and the company's rare-disease portfolio.

BioCryst Pharmaceuticals develops oral medicines for rare diseases, including ORLADEYO for hereditary angioedema.

The further course of trading is shown by the continuously updated real-time quote of BioCryst stock.